Break the silence: Discussing sexual dysfunction
Long a taboo subject among women and many physicians, a new openness about sexual dysfunction is emerging. As the gatekeepers of female reproductive health, Ob/Gyns can play a pivotal role in evaluating and managing these complaints.
- Forty-three percent of U.S. women report being dissatisfied with their sexual functioning.
- Female sexual dysfunction is divided into 4 categories: libido, arousal, orgasm, and pain.
- Factors that contribute to sexual dysfunction are distortion or inflammation of pelvic structures, pelvic or abdominal trauma or surgery, medications, depression, and chronic medical conditions.
- A biopsychosocial model of inquiry is recommended for assessing sexual complaints, emphasizing 4 areas: physical, psychologic, relational, and situational.
In a recent U.S. survey, 43% of female respondents reported being dissatisfied with their sexual functioning, a significantly higher percentage than among male respondents.1 Even more disturbing were separate findings: 71% of adults 25 and older believed their physician would dismiss any sexual concerns they might bring up, while 68% avoided discussing sexual dysfunction with their doctors for fear of embarrassing them.2
A lack of desire for sex is the most common sexual complaint.
These statistics highlight clinicians’ inability to elicit information about and treat sexual disorders in women. Many Ob/Gyns feel they lack the necessary background in fundamental science and psychology to competently evaluate and treat sexual complaints. It is difficult to approach these problems without a complete understanding of the physiology and psychology of female sexual response.
But times are changing. The availability of sildenafil to treat male erectile dysfunction has dramatically increased our patients’ awareness of sexual disorders, as has the open discussion of sexual dissatisfaction on the talkshow circuit. Patients are increasingly likely to expect their health-care providers to evaluate and treat sexual complaints. The following pearls offer a framework for assessing sexual dysfunction, as well as guidelines for therapeutic intervention.
Raising the subject. Although women are gradually opening up about sexual dysfunction, I try not to assume that they will raise the subject themselves. A case in point: Among 308 patients taking selective serotonin reuptake inhibitors (SSRIs), 55% reported sexual dysfunction when the physician asked them about it directly compared with only 14% who reported it spontaneously.3 Many women may not realize sexual complaints are an acceptable subject of discussion for their gynecologic visit, while others may feel uncomfortable talking about sex in general.
I usually begin by asking whether the patient is sexually active and, if she is, whether sex is satisfying to her and her partner. I also ask, “Do you have any concerns about your sexual functioning?” Since this question is sufficiently broad to encompass just about any complaint, it sometimes is helpful in triggering a discussion. If the woman has significant concerns, I follow up with a thorough sexual history.
Assessing your attitudes. As an American College of Obstetricians and Gynecologists (ACOG) technical bulletin points out, the physician should be conscious of any biases he or she holds about certain sexual practices or preferences and should “learn to listen to and discuss ideas and behaviors that conflict with these biases without displaying discomfort.”4 When a patient first begins to talk about her sexual functioning, few things are more troubling than a harried or distracted physician. If you feel that the patient’s concerns require more attention than you are able to provide during that visit, schedule a future appointment to tackle the subject. I usually tell patients that it is too important a subject to try to address in the short time allocated to their current visit.
Exploring the history. A thorough history can make all the difference in pinpointing the underlying cause of a patient’s dysfunction.
Decreased interest in sexual activity is rarely caused by a hormonal imbalance.
I usually have my nurse take a general medical history, including medications. I then meet with the patient in my office (with her clothes on!) and focus on areas such as prior surgeries, endometriosis, prior pelvic surgery or trauma, vaginal or vulvar pain complaints, and depression. Although our intake form asks about domestic violence or a history of physical or sexual abuse, I always make it a point to ask again. Patients are often embarrassed to discuss these issues and will not divulge such sensitive information initially.
The physical exam. I perform a comprehensive physical, including a pelvic exam. This involves checking the introitus for signs of atrophy or vaginitis and palpating the Bartholin’s glands, urethra, and bladder for tenderness. Also, examine episiotomy scars for hypersensitivity and assess the patient for cervical-motion tenderness.
Then evaluate vaginal tone, looking specifically for spasm or difficulty with relaxation of the levator musculature. I want to distinguish between abdominal wall and pelvic-floor muscle tension as potential sources of pain. (The vaginal portion of the examination should be performed with a single digit and only one hand.) Finally, check for masses, and examine the posterior cul-de-sac. Depending on the findings of the examination, I may order laboratory studies or imaging.
Classifying dysfunction. Disorders of female sexual function are divided into 4 areas, described in the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (Table 1). They are:
- disorders of libido, which are central in origin, i.e., they originate in the brain and central nervous system;
- disorders of arousal, which are presumably peripheral/physical (frequently caused by vascular disease and diabetes limiting the vascular supply to the genitalia, or by estrogen deficiency);
- an inability to achieve orgasm; and
- pain disorders.
This division, while not necessarily inaccurate, overlooks the complexity of female sexuality. In women, the libido is better described as a striving for emotional closeness and intimacy rather than simply the sexual drive. Women have fewer spontaneous sexual thoughts and fantasies throughout the biological life span than men and are often unaware of or inattentive to signs of their own physical arousal.5-8 Environmental signals such as romance, a feeling of being cherished, and emotional closeness are more likely to call their attention to physical sensations.
A new model. Trying to assess female sexual complaints using only a biological model is unlikely to be successful. The social environment, hormones, drugs, physical abnormalities, and women’s deep psychological issues all have an impact on their sexual encounters. Thus, I find a biopsychosocial model more useful for assessing complaints. I typically explore 4 areas: physical, psychological, relational, and situational. Using these categories of inquiry, I am able to address the complexities of my patients’ complaints and assess each component of sexual dysfunction in the DSM-IV classification.
Disorders of libido or desire. A lack of desire for sex is the most common sexual complaint and the most difficult to assess quickly. It is typically further classified as either hypoactive sexual desire disorder (HSDD) or sexual aversion disorder (SAD). The first is a deficiency or lack of sexual fantasies or thoughts and/or the desire for sexual activity, while SAD is a phobic aversion to and avoidance of sexual contact with a partner.9 HSDD may be caused by psychological or emotional factors or be secondary to endocrine disorders or other medical problems. In contrast, SAD is usually psychological or emotional in origin, frequently deriving from physical or sexual abuse or childhood trauma.
Often the problem may be related to differing expectations between partners regarding the frequency of their desire for sexual contact. Some people are very happy with weekly or monthly sex, while others think 3 times a day is not enough! And despite media hype to the contrary, decreased interest in sexual activity is rarely caused by a hormonal imbalance. Although testosterone levels decline with age, natural menopause does not trigger a dramatic alteration in them. At menopause, estrogen levels decline much more rapidly than ovarian androgen production, decreasing sex hormone binding globulin (SHBG) and effectively increasing free testosterone levels. However, during the perimenopausal anovulatory time frame, as well as with oral estrogen therapy, SHBG is increased, which may reduce free testosterone levels and contribute to a noticeable and rapid decrease in sexual desire in some circumstances.
Premenopausal women may note decreased libido when taking oral contraceptives (OCs) or other medications that suppress ovarian androgen production. However, in these women, the adrenals remain a source of androgen, which may explain why decreased libido is not a universal complaint in this population. Chronic anxiety, stress (both physical and emotional), depression, chronic pain, and longstanding insomnia all deplete the adrenals and are associated with a decrease in libido. Androgen replacement is rarely successful in these patients.
I usually begin my evaluation by asking the patient if she has experienced discomfort with sexual activity. If she reports that sex has become painful when it wasn’t in the past, a careful physiologic assessment is indicated. I look for genital atrophy, tearing, and vaginismus when evaluating patients with decreased sexual desire.
Relational and situational factors are extremely important in evaluating complaints of diminished libido. Many women are exhausted by their roles as mother, daughter, spouse, and productive member of the workforce. Thus, an assessment of the patient’s social situation is critical. Professional counseling may be required to help women learn to limit their commitments and accept the need for “downtime.”
Management strategies for patients with diminished libido incorporate correction of any vulvar and vaginal atrophy, counseling to improve communication between the patient and her partner, and the identification and treatment of any underlying psychiatric problems. The addition of testosterone may be useful for patients on OCs or oral hormone replacement therapy (HRT) and women with surgical menopause or menopause secondary to chemotherapy.9 In other patients with low libido, the benefit of testosterone is less clear. I prefer compounded 1% or 2% testosterone in PLA cream or petrolatum (depending on whether the patient prefers a cream or an ointment). Patients should apply 1/8 teaspoon to thin skin daily. The ointment may be smoothed directly on the genitalia for added lubrication and rapid improvement in atrophic symptoms. Women who are survivors of domestic and/or sexual abuse will require psychotherapy by a trained counselor.
Arousal disorders. In women, arousal disorders are characterized by an inability to achieve or maintain sexual excitement, which manifests itself as a lack of subjective pleasure or a lack of genital or other somatic responses. 10 Complicating the diagnosis is the fact that the physiologic changes that occur when women are aroused often are difficult to separate from those linked to desire. In general, however, when diminished desire precedes decreased arousal, HSDD is the diagnosis. Even so, just as in men, diseases affecting blood flow or innervation to the genitals can cause arousal disorders in women. Unfortunately for Ob/Gyns, it is much easier to assess these problems in males, since the physiological lack of responsiveness is quite obvious in men.
Women may complain of dryness or decreased sensation in the genitals, or they may experience pain with intercourse. Any of these may be related to reduced engorgement of the tissues and diminished transudation of lubrication across the vaginal epithelium. Estrogen deficiency is a common cause of recent-onset arousal disturbance in patients with a normal level of sexual desire. In perimenopausal and menopausal women, oral or transdermal estrogen replacement in doses sufficient to relieve vasomotor symptoms may not reach the epithelium of the urogenital tissues to correct atrophic changes. In these women, as well as breastfeeding mothers, topical estrogen may improve vaginal elasticity, lubrication, and engorgement. Women taking OCs or long-acting progestational agents also should be carefully assessed for vaginal atrophy. If it is present, topical estrogen will bring dramatic improvement.
Medications known for causing erectile dysfunction in men also should be assessed in women. These include antihypertensives and some antidepressants. In addition, disease states such as hypertension, diabetes mellitus, and peripheral vascular disease may diminish vasodilation and sensation in women as well as men (Table 2). Drugs such as sildenafil may help increase local blood flow in women when erotic stimuli and the central desire for sexual activity remain intact, although the use of sildenafil in women is still in the experimental stages. Recent studies questioning the effectiveness of sildenafil in women may have been limited by the difficulty of clearly distinguishing arousal from desire disorders. Sildenafil will do nothing to improve libido.
As I mentioned earlier, it often is difficult and not particularly useful clinically to distinguish desire from arousal dysfunction. Also, women may be unaware of vascular congestion and lubrication occurring in the genitals, particularly if they have experienced sexual assault. Dissociation is a common defense mechanism in victims of physical violence, and close physical contact and genital touching may trigger this response.